Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Stakeholder Deadline Extended; Are Talks Delayed?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA says stakeholders who want to participate in monthly updates during formal generic drug user fee talks have until late April 2016 to give notice, prompting questions about the negotiation schedule.


Related Content

GDUFA Stakeholder Deadline May Come After Negotiations Conclude
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
Generic User Fee Negotiators Struggling To Meet June Deadline
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts